AN2 Therapeutics (ANTX) Operating Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Operating Expenses for 6 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 8.55% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $37.1 million (down 25.8% YoY), while the FY2025 annual figure was $38.1 million, down 32.89% from the prior year.
• Operating Expenses rose to $10.6 million in Q1 2026 per ANTX's latest filing, from $9.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.8 million in Q4 2023 and bottomed at $7.2 million in Q2 2025.
• Historically, Operating Expenses has averaged $12.8 million across 5 years, with a median of $11.8 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 274.78% — and 2025, when it sank 54.56%.
• AN2 Therapeutics' Operating Expenses stood at $12.5 million in 2022, then surged by 50.81% to $18.8 million in 2023, then slumped by 54.3% to $8.6 million in 2024, then grew by 8.35% to $9.3 million in 2025, then gained by 13.26% to $10.6 million in 2026.
• Business Quant data shows ANTX's Operating Expenses at $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.0 million in Q3 2025.